The Combination of Anti-Thymocyte Globulin and Basiliximab for Haploidentical Hematopoietic Stem Cell Transplantation

Objectives: Identical hematopoietic stem cell transplantation (haplo-HSCT) is associated with a higher risk of graft rejection when compared to matched sibling donor transplantations. Methods: The study included 34 patients who were treated novel regimen combining basiliximab, Anti-thymocyte globulin (ATG) and conventional immunosuppressive in the recipients haplo-HSCT. Results: cumulative incidence grade II–IV III–IV aGVHD was 38.2% 11.8%, while rates limited extensive cGVHD 17.6% 23.5%, respectively. Laboratory evidence CMV EBV reactivation found 9 (26.5%) 6 (18.8%), relapse rate haplo-HSCT 14.7% at 1 year; 1-year OS DFS achieved 58.8% 55.9% patients, Conclusions: results suggested that basiliximab combined low-dose ATG could be promising treatment strategy